IRIS

Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies

Heffler, Enrico;
2022-01-01
2022
CRSwNP
ENT (rhinitis, sinusitis, nasal polyps)
clinical immunology
quality of life
responder analysis
rhinitis
Antibodies, Monoclonal, Humanized
Chronic Disease
Humans
Patient Reported Outcome Measures
Nasal Polyps
Rhinitis
Sinusitis
1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11699/65767
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 7
social impact